NCT07315113RecruitingPhase 1
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 9 Jul 2026
Brief summary (registry, in English)
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 18 Dec 2025
- Start date
- 18 Dec 2025
- Primary completion date
- Dec 2026
- Lead sponsor
- Nuvectis Pharma, Inc.
- Diseases
- Lung cancer
- NCT number
- NCT07315113
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 18
- From 18 Dec 2025 to the primary completion date, Dec 2026
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any contraindications to treatment with osimertinib
Lab values
- Subject's cancer has a known oncogenic driver alteration other than EGFR.
- Known EGFR mutations that cause resistance to osimertinib
Other
- Known human epidermal growth factor receptor 2 (HER2) overexpression
Who the study is looking for
- Provide written informed consent.
- 18 years old or older.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
- Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Not yet recruiting |
| Maryland Oncology Hematology Coordinator of this site? Confirm its status | Calverton | United States | Recruiting |
| Willamette Valley Cancer Institute and Research Center Coordinator of this site? Confirm its status | Eugene | United States | Recruiting |
| NEXT Virginia Coordinator of this site? Confirm its status | Fairfax | United States | Recruiting |
| NEXT Houston Coordinator of this site? Confirm its status | Houston | United States | Recruiting |
| UPMC Hillman Cancer Center Coordinator of this site? Confirm its status | Pittsburgh | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.